Patent ID: 11931414
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 16:
17. The Ligand Drug Conjugate compound of claim 1, wherein the compound is represented by the structure of:, or a salt thereof, wherein
L is an intact antibody or antigen binding fragment of an antibody, thereby defining an antibody Ligand Unit of an antibody drug conjugate (ADC), and S is a sulfur atom from the antibody or the antigen-binding fragment of the antibody;
subscript a is 1 and A is an amino acid residue;
BU is an acyclic Basic Unit so that the dotted curve line is absent, and Ra2 is hydrogen, or
BU together with Ra2 as C1-C6 alkyl and the carbon atom to which both are attached define a cyclic Basic Unit so that the dotted curved line is present; and
R′ is hydrogen or —NO2; and
Xb is —H, —OH, or —NH2,, or
wherein the compound is represented by the structure of:, or a salt thereof, wherein
L is an intact antibody or antigen binding fragment of an antibody, thereby defining an antibody Ligand Unit of an antibody drug conjugate (ADC), and S is a sulfur atom from the antibody or the antigen-binding fragment of the antibody;
subscript a is 1 and A is an amino acid residue;
R′ is hydrogen or —NO2; and
Xb is —H, —OH, or —NH2, or
wherein the compound is represented by the structure of:, or a salt thereof, wherein Ab is an antibody Ligand Unit from an intact antibody or antigen-binding fragment of an antibody; S is a sulfur atom from the antibody or the antigen-binding fragment of the antibody; and subscript p′ is 8,
or
wherein the compound is represented by the structure of:, or a salt thereof, wherein Ab is an antibody Ligand Unit from an intact antibody or antigen-binding fragment of an antibody; S is a sulfur atom from the antibody or the antigen-binding fragment of the antibody; and subscript p′ is 8.